About Event

Having been on the injectable device development journey with leading biopharma over the past 13 years, we have witnessed parenteral evolution from prefilled syringe to autoinjector, to connected devices; as well as the regulatory requirements transitioning from combination products to EU MDR, to the latest human factors and EPR.

With increased emphasis on patient centricity, high volume and long-acting injectables, injectable device engineers are faced with a new set of challenges. The 13^th Injectables Summit is the definitive forum to bring together different disciplines in the Device Design, Engineering, HFE and Quality experts under one roof to share lessons learned and inspire each other to strive towards the common goal of delivering quality drugs to patients faster.

Returning to Boston in October, the 3-day summit will provide you with the clarity on streamlining end-to-end device development journeys, route to global market access with regulatory compliance in mind.

Supported by industry leaders from BioMarin, Takeda, Gilead, Sanofi and more, you will hear the latest case studies in device development across 3 packed days to accelerate your injectable device’s speed to market:

• Learn how to integrate the results of both formative and validation Human Factors Studies into your device development from industry experts in usability and device development
• Hear from BioMarin in how to develop an injectable device with the MDR in mind
• Develop and streamline your cross-functional collaboration to improve the speed-to-clinic of your injectable device
• Gilead will share how they enable a fast scale-up of the injectable device development via a transferable automated manufacture process
• As sustainability questions really begin to develop traction in the injectable device space, listen to industry experts discussing new strategies to improve the sustainability profile of injectable device development